Trial
NCT04230031
Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Wake Forest University Health Sciences
Collaborators
Janssen Research & Development, LLC
Condition
Multiple Myeloma
Intervention
Daratumumab
Why stopped
Difficult enrollment due to changes in standard of care
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-04-21